🇺🇸 FDA
Pipeline program

AMG 732

20230294.01

Phase 2 small_molecule active

Quick answer

AMG 732 for Thyroid Eye Disease is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Thyroid Eye Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials